INTRODUCTION
============

*Clostridium difficile* is a spore forming, toxin producing, gram positive anaerobic bacterium. It was first identified as the cause of antibiotic associated diarrhea in 1978.[@b1-gnl-11-781] Annually, 453,000 new cases occur in the United States with one in four cases occurring in the hospital and a mortality rate of approximately 6%.[@b2-gnl-11-781] Since *C. difficile* infection (CDI) is highly transmissible via the fecal-oral route, strict contact isolation is required per hospital infection control.[@b3-gnl-11-781],[@b4-gnl-11-781] Beyond well-known risk factors, proton pump inhibitor (PPI) use for gastric acid suppression treatment has been an emerging risk factor of CDI.[@b5-gnl-11-781]--[@b16-gnl-11-781] Studies have shown that both PPIs and histamine-2 receptor antagonists (H2RAs) are associated with an increased risk of CDI.[@b9-gnl-11-781],[@b11-gnl-11-781],[@b12-gnl-11-781] Bacterial overgrowth resulting from gastric acid suppression treatment has been suggested as an explanation for the vulnerable gut environment that increases CDI occurrence.[@b17-gnl-11-781] In addition, since 2012, the Food and Drug Administration (FDA) has expressed public concerns of CDI occurrence by gastric acid suppression treatment.[@b18-gnl-11-781] A series of meta-analysis studies supported this public concern of the association between gastric acid suppression and CDI occurrence.[@b19-gnl-11-781]--[@b22-gnl-11-781] Gastric acid suppression can be achieved by two different classes of medications PPI and H2RA. There is an urgent need of comparing CDI risk from PPI and H2RA. In 2012, Kwok *et al*.[@b20-gnl-11-781] reported subgroup analysis that H2RAs were less likely to cause CDI compared to PPIs. However, this meta-analysis encountered a substantial heterogeneity (*I[@b2-gnl-11-781]*, 60% to 85%).[@b20-gnl-11-781] Then after, MacLaren *et al*.[@b23-gnl-11-781] reported greater risk of gastrointestinal (GI) hemorrhage, pneumonia and CDI with PPI compared to H2RA use in an intensive care unit setting. This study limited study participants to critically ill patients on mechanical ventilation.[@b23-gnl-11-781] As such, there is little insight regarding the relation between PPI or H2RA and hospital-acquired CDI. Current meta-analysis is an important addition to medical literature which will guide the health care professional on gastric acid suppression choices in the hospital setting.

MATERIALS AND METHODS
=====================

1. Search strategy
------------------

We performed a literature search using the keywords "*Clostridium*," "Proton pump inhibitor," "Histamine antagonist," "Gastric ulcer," or "Stress ulcer" in various combinations to identify original studies published in English from PubMed, MEDLINE/Ovid, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Google Scholar databases through August 19, 2016.

2. Inclusion and exclusion criteria
-----------------------------------

We included studies that compared the CDI occurrence risks from PPI and H2RA in hospitalized adults. We excluded studies that analyzed patients in nursing homes or living at home.

3. Study selection and data extraction
--------------------------------------

Two authors (M. Azab and J.W.Y.) independently screened titles and abstracts. They obtained full articles that met the inclusion and exclusion criteria and after an independent review, they extracted the data. For all phases, discrepancies were resolved in consultation with three other authors (L.D., D.H.D., and Y.E.). We also hand-searched the eligible articles. Twenty-nine studies relevant to inclusion criteria were added. The actual numbers of CDI cases were collected from tables and manuscript text in each study. When actual data was not presented in certain studies, three authors (M. Ahmed, J.J.C., and X.B.L.) directly contacted corresponding authors of their studies to obtain the data. Since data was from previously published studies, an Institutional Review Board approval was waived. Finally, twelve studies were selected. [Fig. 1](#f1-gnl-11-781){ref-type="fig"} presents the study selection process in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b24-gnl-11-781] A summary of studies is shown in [Table 1](#t1-gnl-11-781){ref-type="table"}.

4. Quality assessment
---------------------

We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess overall quality of evidence for each outcome.[@b25-gnl-11-781] The overall quality of evidence took into consideration the following five domains: risk of bias, consistency, directness, precision, and publication bias.[@b25-gnl-11-781] The GRADE system can be used for rating the quality of evidence (high, moderate, low, and very low).[@b25-gnl-11-781] Meta-analysis from observational studies starts from low quality of evidence. The quality of evidence may decrease when there is serious limitation of any of the five domains. We used optimal information size (OIS) calculations as an objective measure of imprecision for grading evidence, as a priori of risk increase by 25% from PPI with an α=0.05 and β=0.80 compared to CDI occurrence risk from H2RA.[@b26-gnl-11-781] Publication bias was assessed by visual inspection of funnel plots and Egger regression analysis. The GRADEpro software (McMaster University and Evidence Prime Inc., Hamilton, ON, Canada) was used to prepare the quality of evidence as shown in [Table 2](#t2-gnl-11-781){ref-type="table"}.[@b27-gnl-11-781]

5. Data synthesis and analysis
------------------------------

We combined individual study results to calculate the pooled odds ratio (OR) and 95% confidence intervals (CI) using the random effects method.[@b28-gnl-11-781] Between-study heterogeneity was assessed using the *I*^2^ static values of 50%, representing extensive statistical inconsistency. Subgroup analysis was performed to examine effects of medication use purpose, study site, and study design. Meta-regression analysis was performed to predict whether age, gender, or antibiotics use would be associated with hospital-acquired CDI occurrence risk. Baseline characteristics of study participants were aggregated from 12 analyzed studies as shown in [Table 3](#t3-gnl-11-781){ref-type="table"}. To compare the baseline characteristics by CDI status, chi-square analysis for categorical variables and t-test analysis for continuous variable was performed. Kwok *et al*.[@b20-gnl-11-781] performed subgroup analysis of CDI occurrence risks from "PPI vs control" and "H2RA vs control." [Supplementary Table 1](#s1-gnl-11-781){ref-type="supplementary-material"} compared the studies analyzed by current and Kwok's meta-analysis.[@b20-gnl-11-781] All analyses were performed in SPSS version 24 (IBM Corp., Armonk, NY, USA) and Comprehensive Meta-Analysis version 3 (Biostat Inc., Englewood, NJ, USA). A two-sided p-value \<0.05 was considered statistically significant.

RESULTS
=======

A total of 74,132 patients from 12 observational studies were analyzed. Baseline characteristics from pooled study participants are reported in [Table 3](#t3-gnl-11-781){ref-type="table"}. Characteristics were grouped by CDI status: CDI (n=2,235) versus absence of CDI (n=71,897). There was no statistical significance between the participants of CDI and non-CDI except for intensive care unit use. CDI group participants were more likely to be in the intensive care unit than non-CDI group participants (58.32% vs 39.57%, p\<0.001).

[Fig. 2](#f2-gnl-11-781){ref-type="fig"} presents meta-analysis results, CDI risk comparisons between PPI and H2RA. PPIs were associated with an increase in CDI occurrence risk (pooled OR, 1.386; 95% CI, 1.152 to 1.668; p=0.001). Heterogeneity was low (n=4, Q=7.639, p=0.157, *I*^2^=42.81%).

The quality of evidence started low because analyzed studies were all observational. [Fig. 3](#f3-gnl-11-781){ref-type="fig"} presents symmetrical funnel plot consistent with absence of publication bias. No evidence of publication bias by the Egger regression test for all-cause was found. The total number of study patients (17,397) exceeded OIS (6,220). The final quality of evidence remained low because no serious limitation was found in all domains of the GRADE system as shown in [Table 2](#t2-gnl-11-781){ref-type="table"}.

[Fig. 4](#f4-gnl-11-781){ref-type="fig"} presented subgroup analysis results by the purpose of acid suppression therapy. Nine of 12 studies did not specify the purpose of therapy. Only three studies specified the purpose of therapy for prevention of gastric ulcers. PPIs were associated with an increase in CDI occurrence risk in both subgroups (unspecified purpose in [Fig. 4A](#f4-gnl-11-781){ref-type="fig"}: pooled OR, 1.273; 95% CI, 1.085 to 1.495; p=0.003, random effect, *I*^2^=22.9% and prevention purpose in [Fig. 4B](#f4-gnl-11-781){ref-type="fig"}: pooled OR, 2.167; 95% CI, 1.335 to 3.517; p=0.002, random effect, *I*^2^=28.9%). Subgroup analysis by intensive care unit (pooled OR, 1.616; 95% CI, 1.112 to 2.347; p=0.012) and non-intensive care unit (pooled OR, 1.321; 95% CI, 1.11 to 1.563; p=0.001) confirmed consistent results that PPI is associated with higher CDI risk than H2RA. Subgroup analysis by study design confirmed consistency that PPI's CDI risk was higher than that of H2RA: nine case-control studies (pooled OR, 1.166; 95% CI, 1.003 to 1.355; p=0.046); three cohort studies (pooled OR, 1.821; 95% CI, 1.257 to 2.638; p=0.002).

Dubberke *et al*.'s study[@b9-gnl-11-781] could be an outlier resulting in increasing the degree of heterogeneity. When this study was removed from current meta-analysis, the magnitude of pooled OR increased to 1.492 (95% CI, 1.279 to 1.741; p\<0.001) and heterogeneity dropped to near zero (*I*^2^=4.41%). Little is known whether either characteristic study design (nested case control), CDI definition (confirmation by stool toxin assay), or other factor in Dubberke *et al*.'s 2007 study would generate the outlier effect.[@b9-gnl-11-781]

Meta-regression analysis found that there was absence of CDI predictor among age, gender, and antibiotics use. The results of meta-regression analysis were confirmed even at sensitivity analysis using a second-order term for age, gender, and antibiotics use.

DISCUSSION
==========

To the best knowledge, the current meta-analysis is the first meta-analysis comparing CDI occurrence risk in two different stress ulcer treatment and prevention. Current meta-analysis found PPIs increased CDI occurrence risk by 38.6% compared with H2RAs.

Multiple medical societies have raised concerns about the unnecessary use of gastric acid suppression in the hospital.[@b29-gnl-11-781],[@b30-gnl-11-781] Indications for stress ulcer prophylaxis (SUP) in hospitalized patients have been identified in these literature: patients on mechanical ventilation and those with coagulopathy are strongly recommended. Other indications include prior history of GI bleeding, acute renal failure, high dose of steroids, burn, sepsis and increased severity of illness with prolonged intensive care unit stay.[@b29-gnl-11-781],[@b30-gnl-11-781] In critically ill patients, PPIs seem to be more effective than H2RAs in preventing overt upper GI bleeding.[@b31-gnl-11-781] SUP use in lower risk groups is not specified by the professional societies. Indeed, SUP is commonly overused in hospitals, with as many as 71% of patients in general medicine wards receiving some sort of SUP without an appropriate indication.[@b32-gnl-11-781] Anticoagulant therapy has been identified as a risk factor for GI bleeding in hospitalized patients, but the use of SUP has not been found to lower that risk.[@b33-gnl-11-781] Therefore, routine use of SUP in non-ICU services should seriously be reconsidered.[@b32-gnl-11-781],[@b33-gnl-11-781] Moreover, future studies highlighting the comparative efficacy between PPI and H2RA among patients at low GI bleeding risk are needed. Studies have also shown better cost-effectiveness with the use of PPI compared to H2RA for SUP.[@b34-gnl-11-781]--[@b36-gnl-11-781] However, applying these results to current practice would be limited because these studies did not include CDI occurrence as one of the outcomes.[@b34-gnl-11-781]--[@b36-gnl-11-781]

CDI is a significant burden on the health care system. CDI incidence in the United States has increased by approximately 3-fold between 2000 and 2012.[@b2-gnl-11-781],[@b37-gnl-11-781] In 2008, CDI may have resulted in as much as \$4.8 billion in excess healthcare costs in acute-care facilities alone.[@b2-gnl-11-781],[@b37-gnl-11-781] Additionally, it is critical to include cost as main outcome in future studies determining the choice of SUP use. It is also largely unknown which acid suppressive therapy group has better preventive efficacy than the other group in other conditions such as acute renal failure, sepsis, chronic steroid use, and burns. Further studies are urgently needed to compare the efficacy of H2RAs versus PPIs in these patient groups.

Current meta-analysis raised public concerns and suggests future studies. Olsen *et al*.[@b38-gnl-11-781] analyzed nationally representing administrative databases and reported the incidence of CDI in Medicare population was 10-fold higher than that in the privately insured younger patients. Long-term PPI use in nursing homes could increase the risk of CDI occurrence, especially in elderly patients who have been recently discharged from hospital and are more vulnerable to intestinal mucosal injury.[@b39-gnl-11-781] In addition, according to recent nationally representing database analysis, Medicare beneficiaries with recent hospitalization, invasive procedures, urinary tract infection, and pneumonia were more vulnerable to have the CDI.[@b40-gnl-11-781] Public health dimension should identify more high risks and maximize the effectiveness of preventing CDI occurrence attributed by SUP from hospital-level and regional health authorities' perspectives. Suggested future studies would be highlighted by exploring how these high risks on CDI would be influenced when PPI or H2RA is used for SUP.

Our confidence in current meta-analysis results is strengthened by the following few points. First, current meta-analysis has higher homogeneity (*I*^2^=42.81%) compared with previous meta-analyses as shown in [Table 4](#t4-gnl-11-781){ref-type="table"}. Second, current meta-analysis focused on study participants to hospitalized adults. Current analysis findings could be more specifically applied to the development of hospital quality and infection control. Third, current meta-analysis was free of publication bias. For example, newer studies were added after previous meta-analyses were published in 2012 and studies of small number cases (n\<10) were excluded. Lastly, subgroup analysis results confirmed consistency of current meta-analysis results.

We acknowledge several limitations in the current meta-analysis. First, the diagnosis methods of CDI occurrence were not unified by the microbiologic or/and clinical diagnosis. Second, despite being an important risk factor for CDI, we could not obtain information on the specific dose, duration and frequency of the antibiotics used in most of the included studies. We could not perform further analysis to investigate the potential influence of antibiotics use. Third, the purpose of current analysis was not aimed at evaluating other comparative efficacies between PPI and H2RA (e.g., GI bleeding prevention). Finally, more specific H2RA and PPI use data (strength and duration) were not reported. Therefore, current meta-analysis findings should be interpreted with caution.

In conclusions, in either prevention or treatment of stress ulcers, the use of PPIs was associated with increased risk of hospital-acquired CDI occurrence by 38.6% compared to the use of H2RAs.
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###### 

Summary of Studies

  Author (year)                                Study participants   Study site         Study design   *Clostridium difficile* infection risk                    
  -------------------------------------------- -------------------- ------------------ -------------- ---------------------------------------- --------- ------ -----------------
  Shah *et al.* (2000)[@b5-gnl-11-781]         95                   South Wales        Case-control   NA                                       NA               
  Muto *et al.* (2005)[@b6-gnl-11-781]         432                  USA                Case-control   2.4                                      \-        2.0    \-
  Kazakova *et al.* (2006)[@b7-gnl-11-781]     70                   USA                Case-control   3.14                                     0.003     2.69   0.02
  Jayatilaka *et al.* (2007)[@b8-gnl-11-781]   322                  USA                Case-control   2.61                                     \<0.001   1.06   Non-significant
  Dubberke *et al.* (2007)[@b9-gnl-11-781]     1,451                USA                Case-control   4.2                                      \-        3.0    \-
  Aseeri *et al.* (2008)[@b10-gnl-11-781]      123                  USA                Case-control   3.6                                      \<0.001   2.14   0.082
  Howell *et al.* (2010)[@b11-gnl-11-781]      60,531               USA                Cohort         1.74                                     \<0.001   1.53   0.001
  Loo *et al.* (2011)[@b12-gnl-11-781]         2,145                Canada             Case-control   2.64                                     \-        0.98   \-
  Stevens *et al.* (2011)[@b13-gnl-11-781]     7,405                USA                Cohort         4.50                                     \<0.001   1.7    0.25
  Barletta *et al.* (2013)[@b14-gnl-11-781]    148                  USA                Case-control   1.14                                     0.018     NA     
  Barletta *et al.* (2014)[@b15-gnl-11-781]    429                  USA (ICU only)     Case-control   2.19                                     0.005     1.12   0.628
  Ro *et al.* (2016)[@b16-gnl-11-781]          981                  Korea (ICU only)   Cohort         3.0                                      0.003     NA     

PPI, proton pump inhibitor; OR, odds ratio; H2RA, histamine-2 receptor antagonist; NA, not applicable; ICU, intensive care unit.

OR \>1 indicates that either PPI or H2RA increases the risk of *C. difficile* infection compared to no treatment.

###### 

Quality of Evidence

  Outcome                                                         Anticipated absolute effects[\*](#tfn4-gnl-11-781){ref-type="table-fn"} (95% CI)   Relative effect OR[†](#tfn5-gnl-11-781){ref-type="table-fn"} (95% CI)   No. of participants (studies)   Quality of the evidence (GRADE)     Comment   
  --------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------- ----------------------------------- --------- --------------------------------------------------------------------------------------------------------------
  *Clostridium difficile* infection occurrence from PPI vs H2RA   26 per 1,000 (95% CI)                                                              36 per 1,000 (30--43)                                                   1.38 (1.15--1.67)               74,132 (12 observational studies)   2/4 Low   No serious limitations were found in risk of bias, consistency, directness, precision, and publication bias.

CI, confidence interval; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; OR, odds ratio; GRADE, Grading of Recommendations Assessment, Development, and Evaluation.

Number of *C. difficile* infection per 1,000 persons;

OR \>1 indicates *C. difficile* risk from PPIs is higher than the risk from H2RAs.

###### 

Baseline Characteristics of the Study Participants by *Clostridium difficile* Infection Status

  Variable                      *C. difficile* infection (n=2,235)   Absence of *C. difficile* infection (n=71,897)   p-value
  ----------------------------- ------------------------------------ ------------------------------------------------ ---------
  Age, yr                       68.74±3.41                           67.88±2.20                                       0.294
  Sex (male), %                 52.20 (3.28)                         51.96 (2.54)                                     0.539
  Race (white), %               79.28 (13.42)                        78.84 (14.70)                                    0.360
  Intensive care unit stay, %   58.32 (16.72)                        39.57 (7.14)                                     \<0.001
  Antibiotics use, %            86.58 (6.09)                         84.90 (7.13)                                     0.328

Data are presented as mean±SD or observed (SD).

###### 

Meta-Analysis Comparisons of Acid Suppression Therapy and *Clostridium difficile* Infection

  Author (year)                                  Search engine                                                      Acid suppression therapy   No. of studies   Degree of heterogeneity (*I*^2^), %   Pooled effect estimates, OR[\*](#tfn8-gnl-11-781){ref-type="table-fn"} (95% CI)   Quality grading system
  ---------------------------------------------- ------------------------------------------------------------------ -------------------------- ---------------- ------------------------------------- --------------------------------------------------------------------------------- -------------------------------
  Current study                                  PubMed, MEDLINE/Ovid, CINAHL, Web of Science, and Google Scholar   PPI vs H2RA                12               42.81                                 1.386 (1.152--1.668)                                                              GRADE
  Tleyjeh *et al*. (2012)[@b19-gnl-11-781]       MEDLINE, EMBASE, Web of Science, and Scopus                        PPI vs control             51               89.9                                  1.65 (1.47--1.85)                                                                 Newcastle-Ottawa Scale; GRADE
  Kwok *et al*. (2012)[@b20-gnl-11-781]          MEDLINE and EMBASE                                                 PPI vs control             39               85                                    1.74 (1.47--2.85)                                                                 GRADE
  Janarthanan *et al*. (2012)[@b21-gnl-11-781]   MEDLINE                                                            PPI vs control             23               91.93                                 1.648 (1.424--1.908)                                                              MOOSE
  Deshpande *et al*. (2012)[@b22-gnl-11-781]     MEDLINE, CINAHL, Cochrane, Web of Science, and Scopus              PPI vs control             30               87                                    2.15 (1.81--2.55)                                                                 MOOSE

OR, odds ratio; CI, confidence interval; CINAHL, Cumulative Index of Nursing and Allied Health Literature; PPI, proton pump inhibitor; H2RA, histamine-2 receptor antagonist; GRADE, Grading of Recommendations Assessment Development and Evaluations; MOOSE, Meta-Analysis of Observational Studies in Epidemiology.

OR \>1 indicates that PPIs increase the risk of *C. difficile* infection compared to H2RAs (current meta-analysis) or the control (Tleyjeh, Kwok, Janarthanan, and Desphpande's meta-analyses).
